FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection By Ogkologos - February 7, 2025 772 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-67T study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR The RAD51-IF Test Is Feasible for Assessment of the Functional Status... May 7, 2021 EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide August 10, 2020 Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October October 14, 2024 FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 Load more HOT NEWS Cancer in My Community: Addressing Health Disparities in Brazil Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of... News digest – skin cancer deaths, Public Health England plans and... Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors
